Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Apr 27:12:647-655.
doi: 10.2147/PPA.S151752. eCollection 2018.

Developing and piloting an instrument to prioritize the worries of patients with acute myeloid leukemia

John Fp Bridges  1 , Allison H Oakes  1 , Crystal A Reinhart  2 , Ernest Voyard  3 , Bernadette O'Donoghue  3
Affiliations

Developing and piloting an instrument to prioritize the worries of patients with acute myeloid leukemia

John Fp Bridges et al. Patient Prefer Adherence. .

Abstract

Background: Acute myeloid leukemia (AML) is a rapidly progressing blood cancer for which new treatments are needed. We sought to promote patient-focused drug development (PFDD) for AML by developing and piloting an instrument to prioritize the worries of patients with AML.

Patients and methods: An innovative community-centered approach was used to engage expert and community stakeholders in the development, pretesting, pilot testing, and dissemination of a novel best-worst scaling instrument. Patient worries were identified through individual interviews (n=15) and group calls. The instrument was developed through rigorous pretesting (n=13) and then piloted among patients and caregivers engaged in this study (n=25). Priorities were assessed using best-worst scores (spanning from +1 to -1) representing the relative number of times that items were endorsed as the most and the least worrying. All findings were presented at a PFDD meeting at the US Food and Drug Administration (FDA) that was attended by >80 stakeholders.

Results: The final instrument included 13 worries spanning issues such as decision making, treatment delivery, physical impacts, and psychosocial effects. Patients and caregivers most prioritized worries about dying from their disease (best minus worst [BW] score=0.73), long-term side effects (BW=0.28), and time in hospital (BW=0.25).

Conclusion: Community-centered approaches are valuable in designing and executing PFDD meetings and associated quantitative surveys to document the experience of patients. Expert and community stakeholders welcomed the opportunity to share their experiences with the FDA and strongly endorsed implementing this survey nationally.

Keywords: acute myeloid leukemia; best–worst scaling; community engagement; patient-focused drug development; stated-preference.

PubMed Disclaimer

Conflict of interest statement

Disclosure Ernest Voyard and Bernadette O’Donoghue are employees of the LLS. The other authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Project governance.
Figure 2
Figure 2
Key stages of the study. Abbreviation: FDA, US Food and Drug Administration.
Figure 3
Figure 3
Worries about living with AML (best–worst score). Abbreviation: AML, acute myeloid leukemia.
Figure 4
Figure 4
Example of a best–worst scaling choice task.
See this image and copyright information in PMC

References

    1. Saultz JN, Ramiro G. Acute myeloid leukemia: a concise review. J Clin Med. 2016;5(3):E33. - PMC - PubMed
    1. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2014. Bethesda, MD, USA: National Cancer Institute; [Accessed February 28, 2018]. Available from: http://seer.cancer.gov/csr/1975_2013/
    1. Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136–1152. - PubMed
    1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the world health organization (WHO) classification of myeloid neoplasms in acute leukemia: rationale and important changes. Blood. 2009;114(5):937–951. - PubMed
    1. Dohner H, Estey EH, Amadori A, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453–474. - PubMed

LinkOut - more resources